<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; equity</title>
	<atom:link href="http://www.tapanray.in/tag/equity/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Expand Market Share Unleashing Digital Health Potential For All</title>
		<link>http://www.tapanray.in/expand-market-share-unleashing-digital-health-potential-for-all/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=expand-market-share-unleashing-digital-health-potential-for-all</link>
		<comments>http://www.tapanray.in/expand-market-share-unleashing-digital-health-potential-for-all/#comments</comments>
		<pubDate>Mon, 15 Nov 2021 00:00:34 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[adoption]]></category>
		<category><![CDATA[All]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[channel]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[equity]]></category>
		<category><![CDATA[expand]]></category>
		<category><![CDATA[governance]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[inequity]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[marketers]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[platform]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Share]]></category>
		<category><![CDATA[speedy]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10609</guid>
		<description><![CDATA[“Advancement in digital health is currently restricted mainly to economically and socially privileged populations. Those having access, resources and basic digital skills, are reaping disproportionate benefits from the technology and other associated infrastructure available for this purpose. Unfortunately, underserved population, &#8230; <a href="http://www.tapanray.in/expand-market-share-unleashing-digital-health-potential-for-all/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/expand-market-share-unleashing-digital-health-potential-for-all/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>PE Investment In Pharma: The Changing Need Of Due Diligence</title>
		<link>http://www.tapanray.in/pe-investment-in-pharma-the-changing-need-of-due-diligence/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pe-investment-in-pharma-the-changing-need-of-due-diligence</link>
		<comments>http://www.tapanray.in/pe-investment-in-pharma-the-changing-need-of-due-diligence/#comments</comments>
		<pubDate>Mon, 02 May 2016 00:00:19 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[cGMP]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Directors]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[due diligence]]></category>
		<category><![CDATA[equity]]></category>
		<category><![CDATA[FSSAI]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[good]]></category>
		<category><![CDATA[governance]]></category>
		<category><![CDATA[Independent]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[investment]]></category>
		<category><![CDATA[Investor]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[Nutraceuticals]]></category>
		<category><![CDATA[PE]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[private]]></category>
		<category><![CDATA[promoters]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7621</guid>
		<description><![CDATA[From an international perspective, a Bain &#38; Company report of April 2016 highlighted setting a new healthcare M&#38;A record in the year 2015. During this year the total deal value was over 2.5 times higher than the average annual deal value &#8230; <a href="http://www.tapanray.in/pe-investment-in-pharma-the-changing-need-of-due-diligence/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pe-investment-in-pharma-the-changing-need-of-due-diligence/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Wide Gap Between Health Care Needs, And Delivery: Is The Bridge Still Too Far?</title>
		<link>http://www.tapanray.in/wide-gap-between-health-care-needs-and-delivery-is-the-bridge-still-too-far/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=wide-gap-between-health-care-needs-and-delivery-is-the-bridge-still-too-far</link>
		<comments>http://www.tapanray.in/wide-gap-between-health-care-needs-and-delivery-is-the-bridge-still-too-far/#comments</comments>
		<pubDate>Mon, 28 Dec 2015 00:00:00 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2016]]></category>
		<category><![CDATA[28]]></category>
		<category><![CDATA[Ayog]]></category>
		<category><![CDATA[bridge]]></category>
		<category><![CDATA[Budget]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[centric]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[equity]]></category>
		<category><![CDATA[far]]></category>
		<category><![CDATA[February]]></category>
		<category><![CDATA[gap]]></category>
		<category><![CDATA[healtrh]]></category>
		<category><![CDATA[inequity]]></category>
		<category><![CDATA[Lancet]]></category>
		<category><![CDATA[Malnutrition]]></category>
		<category><![CDATA[mortality]]></category>
		<category><![CDATA[needs]]></category>
		<category><![CDATA[Niti]]></category>
		<category><![CDATA[Paper]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Too]]></category>
		<category><![CDATA[Union]]></category>
		<category><![CDATA[wide]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7353</guid>
		<description><![CDATA[“Health inequities which abound in India must be corrected through investments in a robust primary health care system,&#8221; said Professor K Srinath Reddy, chairman, Public Health Foundation of India (PHFI), not too long ago. The equity gap between health care &#8230; <a href="http://www.tapanray.in/wide-gap-between-health-care-needs-and-delivery-is-the-bridge-still-too-far/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/wide-gap-between-health-care-needs-and-delivery-is-the-bridge-still-too-far/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Would “Digital Health Equity” Augment Healthcare For All in India?</title>
		<link>http://www.tapanray.in/would-digital-health-equity-augment-healthcare-for-all-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=would-digital-health-equity-augment-healthcare-for-all-in-india</link>
		<comments>http://www.tapanray.in/would-digital-health-equity-augment-healthcare-for-all-in-india/#comments</comments>
		<pubDate>Mon, 09 Mar 2015 00:00:39 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Accenture]]></category>
		<category><![CDATA[communication]]></category>
		<category><![CDATA[DGHS]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[e-health]]></category>
		<category><![CDATA[equity]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ICT]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Information]]></category>
		<category><![CDATA[portal]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[ZeroDivide]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6408</guid>
		<description><![CDATA[A June 2014 report titled “Digital Health Equity: Humanizing e-Health” published by ‘ZeroDivide’, which helps transform communities through technology in the United States, highlighted that the digital revolution of daily life has significantly impacted healthcare in many parts of the &#8230; <a href="http://www.tapanray.in/would-digital-health-equity-augment-healthcare-for-all-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/would-digital-health-equity-augment-healthcare-for-all-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Patent Conundrum: Ignoring India Will Just Not be Foolhardy, Not An Option Either</title>
		<link>http://www.tapanray.in/patent-conundrum-ignoring-india-will-just-not-be-foolhardy-not-an-option-either/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=patent-conundrum-ignoring-india-will-just-not-be-foolhardy-not-an-option-either</link>
		<comments>http://www.tapanray.in/patent-conundrum-ignoring-india-will-just-not-be-foolhardy-not-an-option-either/#comments</comments>
		<pubDate>Mon, 29 Apr 2013 00:00:25 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[andrew]]></category>
		<category><![CDATA[assessment]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[conundrum]]></category>
		<category><![CDATA[core]]></category>
		<category><![CDATA[direct]]></category>
		<category><![CDATA[Enticing]]></category>
		<category><![CDATA[equity]]></category>
		<category><![CDATA[exit]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[foolhardy]]></category>
		<category><![CDATA[foreign]]></category>
		<category><![CDATA[FTA]]></category>
		<category><![CDATA[Glivec]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Grant]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[HTA]]></category>
		<category><![CDATA[infringement]]></category>
		<category><![CDATA[innovator]]></category>
		<category><![CDATA[investment]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[issue]]></category>
		<category><![CDATA[Lamy]]></category>
		<category><![CDATA[launch]]></category>
		<category><![CDATA[local]]></category>
		<category><![CDATA[lucrative]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[Nexavar]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[OECD]]></category>
		<category><![CDATA[opposition]]></category>
		<category><![CDATA[option]]></category>
		<category><![CDATA[Pascal]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[PIL]]></category>
		<category><![CDATA[post]]></category>
		<category><![CDATA[pre]]></category>
		<category><![CDATA[PwC]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[transfer]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[witty]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2267</guid>
		<description><![CDATA[The recent verdict of the Supreme Court against Novartis, upholding the decision of the Indian Patent Office (IPO) against grant of patent to their cancer drug Glivec, based on Section 3(d) of the Indian Patents Act, has caused a flutter &#8230; <a href="http://www.tapanray.in/patent-conundrum-ignoring-india-will-just-not-be-foolhardy-not-an-option-either/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/patent-conundrum-ignoring-india-will-just-not-be-foolhardy-not-an-option-either/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharmaceutical Brand Building in a Changing Scenario: Thinking Outside the Box</title>
		<link>http://www.tapanray.in/pharmaceutical-brand-building-in-a-changing-scenario-thinking-outside-the-box/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharmaceutical-brand-building-in-a-changing-scenario-thinking-outside-the-box</link>
		<comments>http://www.tapanray.in/pharmaceutical-brand-building-in-a-changing-scenario-thinking-outside-the-box/#comments</comments>
		<pubDate>Mon, 18 Feb 2013 00:00:24 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[advair]]></category>
		<category><![CDATA[brands]]></category>
		<category><![CDATA[building]]></category>
		<category><![CDATA[changing]]></category>
		<category><![CDATA[emotional]]></category>
		<category><![CDATA[equity]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Lipitor]]></category>
		<category><![CDATA[mega]]></category>
		<category><![CDATA[nexium]]></category>
		<category><![CDATA[NovoNordisk]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[paradigm]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[shift]]></category>
		<category><![CDATA[Tapan]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=1405</guid>
		<description><![CDATA[In this article, I shall explore unconventional ways of “Building sustainable Pharmaceutical Brands” thinking  outside the box, after quickly taking you through the “Challenges of Change” in the evolving dynamics of  the Indian branded generic market. A paradigm shift has &#8230; <a href="http://www.tapanray.in/pharmaceutical-brand-building-in-a-changing-scenario-thinking-outside-the-box/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharmaceutical-brand-building-in-a-changing-scenario-thinking-outside-the-box/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Increasing Healthcare Consumption in India with equity</title>
		<link>http://www.tapanray.in/increasing-healthcare-consumption-in-india-with-equity/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=increasing-healthcare-consumption-in-india-with-equity</link>
		<comments>http://www.tapanray.in/increasing-healthcare-consumption-in-india-with-equity/#comments</comments>
		<pubDate>Sun, 13 May 2012 23:00:46 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Consumption]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[equity]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[Increasing]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[insurance]]></category>
		<category><![CDATA[Lancet]]></category>
		<category><![CDATA[medicines. tapan]]></category>
		<category><![CDATA[OECD]]></category>
		<category><![CDATA[oop]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[private]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sectors]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[with]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=94</guid>
		<description><![CDATA[Along with the economic progress of India, healthcare consumption of the population of the country is also increasing at a reasonably faster pace. According to McKinsey India Report, 2007, the share of average household healthcare consumption has increased from 4 &#8230; <a href="http://www.tapanray.in/increasing-healthcare-consumption-in-india-with-equity/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/increasing-healthcare-consumption-in-india-with-equity/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Path-breaking medicines are just not enough… a comprehensive healthcare reform in India is long overdue</title>
		<link>http://www.tapanray.in/path-breaking-medicines-are-just-not-enough-a-comprehensive-healthcare-reform-in-india-is-long-overdue/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=path-breaking-medicines-are-just-not-enough-a-comprehensive-healthcare-reform-in-india-is-long-overdue</link>
		<comments>http://www.tapanray.in/path-breaking-medicines-are-just-not-enough-a-comprehensive-healthcare-reform-in-india-is-long-overdue/#comments</comments>
		<pubDate>Mon, 14 Jun 2010 00:30:49 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[are]]></category>
		<category><![CDATA[breaking]]></category>
		<category><![CDATA[comprehensive]]></category>
		<category><![CDATA[enough]]></category>
		<category><![CDATA[equity]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[inequalities]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[just]]></category>
		<category><![CDATA[long]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Not]]></category>
		<category><![CDATA[outcome]]></category>
		<category><![CDATA[overdue]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[path]]></category>
		<category><![CDATA[Path-breaking]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reform]]></category>
		<category><![CDATA[Socioeconomic]]></category>
		<category><![CDATA[Tapan]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=415</guid>
		<description><![CDATA[The Prime Minister of India, Dr. Manmohan Singh reiterated the following in his speech at the 30th Convocation of PGIMER, Chandigarh on November 3, 2009: ”As in economics, so as in medicine too, it is easy to get lost in &#8230; <a href="http://www.tapanray.in/path-breaking-medicines-are-just-not-enough-a-comprehensive-healthcare-reform-in-india-is-long-overdue/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/path-breaking-medicines-are-just-not-enough-a-comprehensive-healthcare-reform-in-india-is-long-overdue/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
